The Anti-tumor Effect of Metformin And Atorvastatin in Breast Cancer

• Status: Not yet recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study aims at evaluating and comparing the anti-tumor effects of metformin and statins (hydroxyl-methyl-glutaryl-CoA reductase inhibitors) in patients with non-metastatic breast cancer (stage I, II, & III).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Atorvastatin; Metformin

Criteria

Inclusion Criteria:

• Patients with radiologically and histologically (biopsy) confirmed diagnosis of breast cancer and with stage I, II, and stage III breast cancer according to the American Joint Committee on Cancer (TNM staging system of breast cancer).

• Patients with no contraindication for chemotherapy, metformin, or statins

• Females aged ≥ 18 years old

• Performance status < 2 according to the Eastern Cooperative Oncology Group (ECOG) score

Exclusion Criteria:

• Patients with metastatic breast cancer (stage IV)

• Pregnant or lactating women.

• Patients with hepatic or renal impairment.

• Patients with myopathy.

• Patients with any condition predispose to acidosis (COPD, heart failure, ….)

• Patients who had dementia, mental retarded, and any psychiatric condition that would prohibit the understanding or signing of informed consent.